Medgenics, Inc. Provides Clinical and Regulatory Update  
11/9/2011 8:24:33 AM

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided a clinical update on the Company’s progress with the development of its Biopump which is being developed for the treatment of a range of chronic diseases including anemia and hepatitis C.